NCT03636932View on ClinicalTrials.gov

RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

February 4, 2021

Study Completion Date

May 23, 2023

Conditions
Chronic Kidney Diseases
Interventions
DRUG

N-acetylcysteine (NAC)

Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.

DRUG

Placebo

Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.

BIOLOGICAL

Blood sample

Circulating tissue factor assay

BIOLOGICAL

Blood sample

The test of pro-coagulant activity of the tissue factor

Trial Locations (1)

13354

Assistance Publique Hôpitaux de Marseille, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER

NCT03636932 - RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine | Biotech Hunter | Biotech Hunter